Formulation Development
Ardena & RiboPro Forge Strategic Alliance to Support the RNA Revolution With End-to-End Manufacturing of Advanced mRNA & LNP Solutions
Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at…
Adare Pharma Solutions Announces Divestiture of Postbiotics Pioneer Adare Biome to dsm-firmenich
Adare Pharma Solutions recently announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in….
Zealand Pharma Submits NDA to US FDA for Dasiglucagon in Congenital Hyperinsulinism
Zealand Pharma A/S recently announced the submission of a New Drug Application (NDA) to the US FDA for dasiglucagon for the prevention and treatment of…
Oxford BioTherapeutics Initiates Phase 1b Clinical Trial for OBT076 in Patients With Advanced Solid Tumors
Oxford BioTherapeutics recently announced it has initiated a Phase 1b combination trial evaluating its lead candidate, OBT076 - a CD205 targeting ADC - and Agenus’…
F-star Announces Strategic Collaboration & License Agreement With Takeda
F-star Therapeutics, an invoX company, recently announced it has entered into a strategic discovery collaboration and licensce agreement with….
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Palisade Bio, Inc. recently announced the completion of patient enrollment in its dose optimization study of LB1148. “Achieving our enrollment target in this study is an…
Enterome Announces First Patient Dosed in Phase 1/2 Trial With Third OncoMimics Immunotherapy in Metastatic Colorectal Cancer
Enterome recently announced the first patient was dosed in the Phase 1/2 AUDREY trial evaluating EO4010, the company’s third OncoMimics candidate, for the treatment of patients with….
SciSparc Receives Approval to Conduct Phase 2b Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
SciSparc Ltd. recently announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (BfArM) for its Phase…
WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP
Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to….
Urica Therapeutics Announces Topline Data From Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the US
Urica Therapeutics, Inc. recently announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the US. The randomized, placebo-controlled Phase…
Curia Wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recently announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan. “We are very…
Berkshire Sterile Manufacturing Announces Plans to Expand Lyophilization Capacity
Berkshire Sterile Manufacturing (BSM) expects to double their lyophilization capacity for their fully automated, isolator-based filling line to meet new demand. A second lyophilizer will…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
Harpoon Therapeutics, Inc. recently announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of…
Inozyme Pharma Announces Dosing of First Infant With ENPP1 Deficiency in Phase 1b Trial
Inozyme Pharma, Inc. recently announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency.…
MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
Larkspur Biosciences recently reported one of their lead programs is a first-in-class B cell checkpoint, TIM-1. This announcement follows the publication by Larkspur co-founder Vijay…
Clene Announces Publication of Phase 2 CNM-Au8 Clinical Data for the Treatment of ALS
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc. recently announced The Lancet’s journal eClinicalMedicine has published combined detailed analyses of the Phase 2…
Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in….
XOMA Acquires Royalty & Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) & Phase 2 Oncology Asset
XOMA Corporation recently announced it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick…
